Connected data gives you a clearer picture
At Evaluate we collect, calibrate and connect the pharmaceutical world's data.
Blog
Blog Library
Five Questions about the Future of Gene Editing
Gene editing has been in and out of the news since Crispr hit the headlines a decade ago. It’s been anything from the next big thing to a borderline miracle to a…
BioSci Deal of the Month - Spero Therapeutics & GSK
In September of 2022, GSK and Spero Therapeutics entered into an exclusive license agreement for late-stage antibiotic asset, Tebipenem HBr.
PODCAST: Clinical showdowns in the second quarter
Got 10 minutes (well, 12 if we’re being precise)? Grab a cuppa and listen to our latest podcast diving into some of the big catalysts we’ll be looking out for in the…
In case you missed it: Three things we learned from our orphan drug webinar
Missed our webinar on orphan drugs and the impact of the Inflation Reduction Act? Well, you missed a lot but here are a few takeaways to help you catch up. And the full…
BioSci Deal of the Month - Kainos Medicines & Emmaus Life Sciences
In February of 2021, Emmaus Life Sciences and Kainos Medicine entered into an agreement to jointly develop Kainos’ patented IRAK4 inhibitor (KM10544).
Podcast: A new audio formulation for our PD(L)anner
Our PD(L)anner reports are now hitting the airwaves.
Meet the Evaluate Team: Lisa Urquhart
In this edition of Meet the Team, we’re chatting to someone who is bordering on national treasure territory. Lisa Urquhart is the editor of Evaluate Vantage where she…
It’s all about impact: why orphan drugs are a big deal for patients and pipelines
300 million people worldwide are living with a rare disease. The "orphan" drugs created to treat them have been a fast-growing part of the pharma market for…
Meet the Evaluate Team: Tom Moore
It’s Meet the Team time again and to kick off 2023 we’re hopping across the pond to meet one of our US-based team members, Tom Moore, SVP Account Management - Americas.…
In case you missed it: Three things we learned from the Evaluate Vantage 2023 Preview webinar
Missed out latest webinar? Fear not, here are three things we learned from the 2023 Preview discussion. And the webinar is available on demand now.